Middle East and Africa Joint Pain Injection Market

Market Introduction

The Middle East and Africa joint pain injection market is

a

highly fragmented market with the presence of considerable regional and local players providing numerous solutions for companies investing in the market arena. Hyaluronic acid injections offered by companies are usually administered for treating sports injuries, as they aid in pain relief, reduce inflammation, and improve joint function. Corticosteroids are also used to treat sports-related injuries. Sports injuries are caused due to direct impact, or the application of force that is larger than the body part can withstand. The most common sport injuries are sprains, strains, joint injuries, and bruises. People involved in football, bicycling, basketball, playground, and soccer activities contributed to the highest number of emergency department (ED) visits in that year. It also states sport injuries affect over thousands of youth population engaged in various sports.

Several Middle Eastern and African countries witnessed an unprecedented rise in the number of COVID-19 cases which led to the discontinuation of several business operations and manufacturing activities of various healthcare products, including joint pain injections, which negatively impacted the joint pain injection market during the early months of 2020. Shortage of hospital supplies also accelerate the criticality of the condition. During the pandemic, the focus of healthcare professionals was only limited to the covid management, which substantially hampered the number of elective surgeries in the region. Moreover, implementation of social distancing policies resulted into limited patients visits to orthopedic centers, which drastically impacted the demand and adoption of joint pain injections in Middle East and Africa. Apart from this, a huge population already face a growing burden of non-communicable diseases, making them more vulnerable to the virus. Moreover, economic uncertainties and ongoing conflicts are worsening the condition in the region.

Middle East and Africa Joint Pain Injection Strategic Insights

Strategic insights for the Middle East and Africa Joint Pain Injection provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East and Africa Joint Pain Injection Report Scope

Middle East and Africa Joint Pain Injection Regional Insights

The geographic scope of the Middle East and Africa Joint Pain Injection refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Market Overview and Dynamics

The joint pain injection market in Middle East and Africa is expected to grow from US$ 49.82 million in 2021 to US$ 75.57 million by 2028; it is estimated to grow at a CAGR of 6.1% from 2021 to 2028. Countries in Middle East and Africa are emerging as attractive outsourcing locations for pharmaceuticals and biopharmaceuticals industries. Flourishing domestic pharmaceutical market and increasing number of pipeline drugs are further opening new avenues for the contract manufacturers as well as generic drug manufacturing in the region. Saudi Arabia is among the largest economies in the Middle East region. Country's economy is most flourishing, which is supported by the diversified initiatives and increasing population. The growing demand for generic production and increasing international players' expansions into the country have provided substantial growth for the pharmaceutical industry. Additionally, the country-based companies have initiated importing raw materials for producing a generic version of the foreign-made branded medicines. The aging population in the UAE is likely to demand joint replacement procedures in the UAE. In 2017, Dubai Health Authority indicated the country's older population - people aged 65 and over - would increase from 6% to 29% by 2050. Furthermore, rising prevalence of osteoarthritis is likely to demand for joint replacement therapies in the UAE. Osteoarthritis is one of the prominent causes of disability in the UAE with around 50% of the old age population (people above 65 years and above), suffering from the chronic conditions. Some 25% of people over the age of 60 years have significant pain and disability caused by osteoarthritis. These factors are expected to have positive impact on the growth of the UAE joint pain injection market during the forecast period.

Key Market Segments

Based on drugs, the hyaluronic acid segment accounted for the largest share of the Middle East and Africa joint pain injection market in 2020. Based on joint type, the knee segment accounted for the largest share of the Middle East and Africa joint pain injection market in 2020. Based on distribution channel, the hospitals pharmacies segment accounted for the largest share of the Middle East and Africa joint pain injection market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the Middle East and Africa joint pain injection market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report include Bioventus Inc.; Fidia Pharma USA Inc.; Ferring B.V.; Sanofi; Anika Therapeutics, Inc; and Teva Pharmaceutical Industries Ltd.

Reasons to buy report

• To understand the Middle East and Africa joint pain injection market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Middle East and Africa joint pain injection market
• Efficiently plan M&A and partnership deals in Middle East and Africa joint pain injection market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Middle East and Africa joint pain injection market
• Obtain market revenue forecast for market by various segments from 2020-2028 in Middle East and Africa region.

Middle East and Africa Joint Pain Injection Market Segmentation

Middle East and Africa Joint Pain Injection Market -B

y Drugs

• Hyaluronic Acid
• Corticosteroid
• Others

Middle East and Africa Joint Pain Injection Market -By Joint Type

• Knee
• Foot and Ankle
• Shoulder and Elbow
• Hip
• Others

Middle East and Africa Joint Pain Injection Market -By Distribution Channel

• Retail Pharmacies
• Hospitals Pharmacies
• Others

Middle East and Africa Joint Pain Injection Market – By Country

• South Africa
• Saudi Arabia
• UAE
• Rest of Middle East and Africa

Middle East and Africa Joint Pain Injection Market – Company Profiles

• Bioventus Inc.
• Fidia Pharma USA Inc.
• Ferring B.V.
• Sanofi
• Anika Therapeutics, Inc.
• Teva Pharmaceutical Industries Ltd.